Search clinical trials for: Nirmatrelvir/Ritonavir

Total 892 results

1
2
3
4
5
6
7
8
9
10
...
17
18
›

Pfizer

Active, not recruiting

A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.

COVID-19

United States
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Biological Availability

Belgium
Pfizer

Withdrawn

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

Healthy Participants | Biological Availability
Pfizer

Completed

A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women

Healthy Participants

Belgium
ANRS, Emerging Infectious Diseases
University Hospital, Geneva

Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (OPTICOV)

COVID-19 | Immunodeficiency

Norway, France, Italy
Karolinska Institutet
Karolinska University Hospital; Pfizer

Completed

ImPROving Quality of LIFe in the Long COVID Patient (PROLIFIC)

COVID-19 | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | POTS - Postural Orthostatic Tachycardia Syndrome | Postinfectious Inflammation | Postinfectious Disorder

Sweden
Calmy Alexandra
ANRS, Emerging Infectious Diseases

Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (SWISS OPTICOV)

COVID-19 | Immunodeficiency

Switzerland
Kanecia Obie Zimmerman

Completed

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (RECOVER-VITAL)

Long COVID | Long COVID-19

United States
Pfizer

Withdrawn

A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

COVID-19 Drug Treatment
Chinese University of Hong Kong

Completed

Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

COVID-19 | Chronic Kidney Disease stage4 | Chronc Kidney Disease Stage 5

Hong Kong
Chinese PLA General Hospital

Recruiting

Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease (ESPTCSCKD)

COVID-19 | Renal Insufficiency, Chronic

China
The First Affiliated Hospital of Zhengzhou University
Luoyang Central Hospital; Nanyang Central Hospital; The Fifth People's Hospital... and other collaborators

Completed

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

COVID-19 | Azvudine

China
Universidade do Porto
Centro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS); Rede... and other collaborators

Active, not recruiting

Effectiveness and Safety of New Oral Antivirals for COVID-19 (ESOA-19)

COVID-19

Portugal
University of Oxford

Recruiting

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PLATCOV)

COVID-19

Thailand, Brazil, Pakistan, Nepal, Laos
Pfizer

Completed

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

COVID-19

Bahrain
Pfizer

Completed

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

COVID-19

United States
Pfizer

Completed

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

Covid-19

Saudi Arabia
Traws Pharma, Inc.

Recruiting

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

COVID - 19

Australia, South Korea, Taiwan, Uzbekistan
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19

Coronavirus Disease 2019 (COVID-19)
National Cheng-Kung University Hospital

Completed

Saliva PCR in Pregnant Women with COVID-19

Coronavirus Disease 2019 (COVID-19) Pneumonia

Taiwan
Mount Sinai Hospital, Canada
Unity Health Toronto; Niagara Health System; Kingston Health Sciences Centre...

Recruiting

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial (DEFEND)

SARS CoV-2 Post-Acute Sequelae

Canada
Azienda Ospedaliera Universitaria Integrata Verona
Agenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di...

Completed

Non-inferiority Trial on Treatments in Early COVID-19

COVID-19

Italy
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Healthy

Egypt
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Healthy Participants | Biological Availability

United States
National Taiwan University Hospital

Not yet recruiting

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients (SARS-CoV-2)

COVID-19 | SARS-CoV-2 | Immunocompromised

Taiwan
Pfizer

Completed

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

COVID-19

United States, Taiwan, Italy, Canada, Greece
Pfizer

Completed

A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin

Healthy Volunteers | Pharmacokinetics

Belgium
Pfizer

Recruiting

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

COVID-19

United States, South Africa, Japan, United Kingdom, Mexico, Bulgaria, Puerto Rico
RenJi Hospital

Completed

The Safety of Paxlovid in Hemodialysis Patients With Covid-19 (SPHPS)

Safety Issues

China
Stanford University
Pfizer

Completed

Paxlovid for Treatment of Long Covid (STOP-PASC)

Long COVID | Post-acute Sequelae of SARS-CoV-2 Infection

United States
Pfizer

Terminated

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

COVID-19

United States
Pfizer

Terminated

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

COVID-19

United States
Pfizer

Completed

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

COVID-19 (Coronavirus Disease 2019)

United States
Pfizer

Completed

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

COVID-19

Spain, United States, Australia, Canada, Bulgaria, Slovakia, Mexico, Hungary, Brazil
Pfizer

Completed

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

SARS-CoV-2 Infection

Japan
Mclean Hospital

Withdrawn

Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons

Alcohol Dependence | Alcohol Abuse | Heavy Drinking Days

United States
Well- Konnect Healthcare Services and Research...
All of Us Research Program at the National Institute of Health

Recruiting

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

COVID-19, Long Haul

United States
University of Liverpool
University of Cambridge; Royal Liverpool University Hospital; Liverpool School...

Recruiting

AGILE (Early Phase Platform Trial for COVID-19) (AGILE)

Covid19

United Kingdom, South Africa
University of Oxford

Completed

Mass Screening and Treatment for Reduction of Falciparum Malaria (MSAT)

Plasmodium Falciparum Malaria

Thailand
Haukeland University Hospital
University of Oslo; Oslo University Hospital; University of Bergen; Norwegian University... and other collaborators

Active, not recruiting

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (PanoramicNOR)

COVID-19 | SARS-CoV2 Infection | Post COVID-19 Condition, Unspecified

Norway
Pfizer

Withdrawn

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 (EPIC-HOS)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19) | Immunocompromised | Hospitalization | Child, Hospitalized

United States, Bulgaria
Kanecia Obie Zimmerman

Completed

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (RECOVER-VITAL)

Long COVID | Long Covid19

United States, Puerto Rico
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital; First People's Hospital of Lin'an District; First People...

Recruiting

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Hospitalized Patients

China
Pfizer

Completed

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Healthy Participants

United States
Pfizer

Completed

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

Bioavailability

United States
Shandong Provincial Hospital
Gansu Provincial Hospital; The Affiliated Hospital Of Southwest Medical University and other collaborators

Recruiting

A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

COVID-19

China
Vigonvita Life Sciences

Completed

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

COVID-19

China
Promomed, LLC
Sponsor GmbH

Completed

Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population

COVID-19

Russian Federation
Pfizer

Completed

A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.

Healthy Participants

China
Pfizer

Completed

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Healthy Participants

United States

1
2
3
4
5
6
7
8
9
10
...
17
18
›

Subscribe